ClinicalTrials.gg
Not yet recruitingNCT06591728Updated Feb 5, 2025

PCA Loading Time Before Knee Prosthetic Joint Infection Revision

An interventional study of Oral PCA in Prosthesis-Related Infections, sponsored by Dr. Dean Reeves Clinic. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-05.

Sponsored by Dr. Dean Reeves Clinic · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Proof of principle pilot study of the effect of dietary nutritional loading of protocatechunic acid (PCA) on the health and welfare of individuals with prosthetic joint infection (PJI), as measured by standard biomarkers

Read the detailed description

Our purpose in the pre-surgery serial aspiration study is to determine the optimal PCA loading time duration for those with knee PJI with planned single or two stage revision.Our hypothesis, related to changes in structure and function as a result of PCA administration is that dietary nutritional loading of this nutraceutical PCA via the oral route will benefit the health and welfare of such a subject and alter the function and or structure of the human body having a PJI, as measured by improvemen in a pain biomarker, and one or more laboratory-based biomarkers.

02

Conditions studied

  • Prosthesis-Related Infections
03

In context

Prosthesis-Related Infections

35 studies on the registry are indexed under Prosthesis-Related Infections; 10 are open to participants now.

This study's planned enrollment of 10 is below the median of 193 across 20 interventional studies indexed under Prosthesis-Related Infections.

Browse Prosthesis-Related Infections studies →

Lead sponsor

Dr. Dean Reeves Clinic is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • More than 3 weeks after total knee arthroplasty
  • One or more symptoms of injection, including redness, swelling, pain, increasing range of motion loss, fever, nausea, and loss of appetite.
  • WBC count of aspiration >50,0000 cells per μL

Exclusion criteria

Exclusion Criteria:

  • Not willing to undergo blood draw and joint needle aspiration weekly up to 4 weeks
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Other
    Oral PCA

    Dietary Supplement: Oral PCA

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Walking Pain 0-10 NRS

    Walking pain change from time 0 to weekly follow-ups from 1-4

    Time frame: 0,1, 2, 3, and 4 weeks

  2. Change in CRP

    Blood CRP change from time 0 to weekly follow-ups from 1-4

    Time frame: 0,1, 2, 3, and 4 weeks

  3. Change in ESR

    Blood ESR change from time 0 to weekly follow-ups from 1-4

    Time frame: 0,1, 2, 3, and 4 weeks

  4. Change in WBC count in aspirate

    Total WBC count change in periprosthetic aspirate

    Time frame: 0,1, 2, 3, and 4 weeks

  5. Bacterial colony count in aspirate

    Colony count graded as 0 (No colonies), 1 (Few colonies), 2 (moderate growth) 3(heavy growth), and 4 (too numerous to count)

    Time frame: 0,1, 2, 3, and 4 weeks

Secondary outcomes

  1. CXCL9

    Change in Immunity Factor CXCL9 from 0 to 3 months

    Time frame: 0 and 3 months

  2. HbA1c

    Change in HbA1c from 0 to 3 months

    Time frame: 0 and 3 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Aug 2025, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2024
First posted
Sep 19, 2024
StartEst.
Mar 1, 2025
Primary completionEst.
Aug 2025
CompletionEst.
Dec 2025
Last update
Feb 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06591728
Lead sponsor
Dr. Dean Reeves Clinic
Collaborators
Lanny Johnson, M.D., Leo Whiteside, M.D.
Responsible party
Dr. Dean Reeves (Principal Investigator, Dr. Dean Reeves Clinic) — Principal investigator
First posted
Sep 19, 2024
Start date
Mar 1, 2025 (estimated)
Primary completion
Aug 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Feb 5, 2025

Study contacts

Kenneth D Reeves, M.D.
Contact
deanreevesMD@gmail.com
9139637750
Lanny Johnson, M.D.
Contact
drlannyjohnson@gmail.com
5172851812
Kenneth D Reeves
principal investigator · K. Dean Reeves, M.D., P.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pyrrolidonecarboxylic Acid

Start the discussion